Target intelligence / Profile preview

Hepatic de novo lipogenesis pathway (DNL)

Target
DNL
Molecular classification
Other (Metabolic Pathway)
01

Overview

The **hepatic de novo lipogenesis pathway** refers to the series of biochemical reactions in which excess dietary carbohydrates are converted into fatty acids within hepatocytes. This process begins with acetyl-CoA generated from carbohydrate catabolism and proceeds through several enzymatically catalyzed steps—primarily involving acetyl-CoA carboxylase and fatty acid synthase—to produce saturated long-chain fatty acids such as palmitate. These newly synthesized fats can be stored in the liver or exported as triglycerides. In healthy individuals, this process helps maintain energy balance and glucose homeostasis. However, dysregulation—often driven by high sugar intake or insulin resistance—leads to increased fat accumulation in the liver (**hepatic steatosis**) and contributes significantly to conditions like nonalcoholic fatty liver disease (**NAFLD**), type 2 diabetes mellitus, metabolic syndrome, cardiovascular risk factors such as dyslipidemia and inflammation. Key transcriptional regulators include sterol regulatory element-binding protein 1c (**SREBP‐1c**) activated by insulin signaling and carbohydrate response element-binding protein (**ChREBP**) stimulated by carbohydrate intake; both upregulate expression of genes encoding critical enzymes for this synthetic route[1][2]. Pharmacological interventions aim at inhibiting pivotal steps within this cascade—for example using omega‐3 polyunsaturated fats that suppress DNL activity—or direct enzyme inhibitors under clinical investigation for NAFLD/NASH therapy.[6] Circulating levels of certain saturated/monounsaturated fats serve both as functional readouts ("biomarkers") for patient selection/monitoring efficacy during clinical trials.[5]

Other names
De novo lipogenesis (DNL)Hepatic DNLLiver fatty acid synthesis
02

Mechanism of action

Mechanisms involve inhibition or modulation of key enzymes such as acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and stearoyl-CoA desaturase 1 (SCD1) to reduce hepatic lipid synthesis and accumulation.

03

Biological functions

Fatty acid synthesisEnergy storageRegulation of glucose homeostasisContribution to cellular membrane structure
04

Disease associations

Nonalcoholic fatty liver disease (NAFLD)Metabolic syndromeType 2 diabetes mellitusInsulin resistanceCardiovascular disease risk factors (via dyslipidemia and inflammation)
05

Safety considerations

Potential safety concerns with pharmacological inhibition include disruption of essential lipid metabolism leading to adverse effects on cell membranes or energy balanceoff-target effects due to broad impact on metabolic pathways
06

Interacting drugs

Omega‐3 fatty acids

2 more in the full profile.

07

Biomarkers

Palmitic acid (16:0)Palmitoleic acid (16:1n‐7)Stearic acid (18:0)Vaccenic acidOleic acidVLDL-TAG concentrations

Beyond the preview

Go deeper on Hepatic de novo lipogenesis pathway (DNL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepatic de novo lipogenesis pathway (DNL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call